Scholarlink

<p>Myocardial inflammation is a key driver of adverse outcomes; yet its clinical recognition remains challenging because of heterogeneous presentation and non-standardised prognostic frameworks. While prior studies linked troponin and late gadolinium enhancement (LGE) by cardiovascular magnetic resonance imaging (CMR) to outcomes, the relative prognostic value of individual non-invasive markers has not been systematically evaluated. We systematically evaluated the prognostic value of biomarkers and non-invasive imaging variables in patients with clinically suspected myocardial inflammation presenting to tertiary centres and referred for CMR diagnostic evaluation. The primary endpoint was major adverse cardiovascular events (MACE). A total of 722 patients (median age: 50 years [IQR: 40–61]; 422 males [58%]) were included. Over a median follow-up of 19 months (IQR: 15–23), 64 patients (9%) experienced MACE. In univariable analyses, age, haematocrit, C-reactive protein, high-sensitivity troponin T (hs-TropT), ventricular function, cardiac volumes and mass, late gadolinium enhancement (LGE), and native T1 and T2 values were associated with the endpoint. In multivariable Cox regression, native T2, hs-TropT, and LGE were independently predictive of MACE (model χ² = 81.64, <i>p</i> &lt; 0.001). Patients with high-grade myocardial inflammation had the highest mid-term event risk (<i>p</i> &lt; 0.001). Among patients with negative troponin, T2 and left ventricular end-diastolic volume (LVEDV), but not LGE, were predictive of MACE. In patients with clinically suspected myocardial inflammation, standardised CMR-based markers provide independent and incremental prognostic information, supporting their role in improved risk stratification beyond composite criteria.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes by cardiovascular magnetic resonance in patients with clinically suspected myocardial inflammation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月18日

查看全文
  • Eike Nagel,
  • Gerry Carr-White,
  • Andreas Rolf,
  • Hafisyatul Zainal,
  • Moises Vasquez,
  • Hui Zhou,
  • Luca Arcari,
  • Faraz Pathan,
  • Silvia Valbuena,
  • Rocio Hinojar,
  • Eleftherios Vidalakis,
  • Michael Kolentinis,
  • Tommaso D’Angelo,
  • Elen Sahara,
  • M. Ludovica Carerj,
  • Julia Treiber,
  • Michael Marber,
  • Till Keller,
  • Valentina O. Puntmann

摘要

Myocardial inflammation is a key driver of adverse outcomes; yet its clinical recognition remains challenging because of heterogeneous presentation and non-standardised prognostic frameworks. While prior studies linked troponin and late gadolinium enhancement (LGE) by cardiovascular magnetic resonance imaging (CMR) to outcomes, the relative prognostic value of individual non-invasive markers has not been systematically evaluated. We systematically evaluated the prognostic value of biomarkers and non-invasive imaging variables in patients with clinically suspected myocardial inflammation presenting to tertiary centres and referred for CMR diagnostic evaluation. The primary endpoint was major adverse cardiovascular events (MACE). A total of 722 patients (median age: 50 years [IQR: 40–61]; 422 males [58%]) were included. Over a median follow-up of 19 months (IQR: 15–23), 64 patients (9%) experienced MACE. In univariable analyses, age, haematocrit, C-reactive protein, high-sensitivity troponin T (hs-TropT), ventricular function, cardiac volumes and mass, late gadolinium enhancement (LGE), and native T1 and T2 values were associated with the endpoint. In multivariable Cox regression, native T2, hs-TropT, and LGE were independently predictive of MACE (model χ² = 81.64, p < 0.001). Patients with high-grade myocardial inflammation had the highest mid-term event risk (p < 0.001). Among patients with negative troponin, T2 and left ventricular end-diastolic volume (LVEDV), but not LGE, were predictive of MACE. In patients with clinically suspected myocardial inflammation, standardised CMR-based markers provide independent and incremental prognostic information, supporting their role in improved risk stratification beyond composite criteria.